#UN; #WHO; #AstraZenecaCovidVaccine; #JohnsonAndJohnsonsCovidVaccine
New York/Canadian-Media: The UN World Health Organization (WHO) said on Friday that it was aware of blood clot concerns linked to “a specific batch” of AstraZeneca/Oxford COVID-19 vaccine, but maintained that to date, no-one has died from any coronavirus vaccine.
Cambodia takes delivery of 324,000 doses of the AstraZeneca COVID-19 vaccine through the COVAX Facility. © UNICEF/Antoine Raab
“As of 9 March, there have been over 268 million doses of vaccine delivered since the start of the pandemic, and based on data reported – that’s data reported to WHO by national governments - no causes of death have been found or been caused by COVID-19 vaccines to date”, said spokesperson Dr Margaret Harris.
Speaking via videoconference in Geneva, Dr Harris noted that the WHO’s independent expert global advisory board, SAGE, was currently assessing reports on the AstraZeneca vaccine and that those findings would be made public as soon as they were available.
Causal link not shownBlood clotting episodes are common in people “so it’s not clear if this was something that was going to happen”, or whether the vaccine was responsible, the WHO spokesperson explained.
“A causal relationship ….has not been shown”, she said, while also underscoring that the European Union medical agencies’ risk assessment committee, Pharmacovigilance, had also decided that the vaccine’s benefits “continue to outweigh the risks”.
“The panel had taken the position that the jab should continue to be administered, while an investigation of cases of these thrombo-embolic events is ongoing”, Dr Harris continued.
Countries that have reportedly paused their inoculation campaigns include Austria, Denmark, Estonia, Lithuania Norway, Iceland and Thailand.
Hundreds of vaccine candidates
According to the WHO COVID-19 vaccine tracker, there are 81 vaccines in clinical development and more than 180 in the pre-clinical development phase.
To date, WHO has approved two vaccines for emergency use against COVID-19: the Pfizer/BioNTech vaccine - approved on 31 December 2020 – and two versions of the AstraZeneca/Oxford vaccine, on 15 February 2021.
The Chinese Sinovac jab is currently in the last stage of clinical evaluation and may be approved for use by the end of the month, Dr Harris said
“Certainly, we are looking at the Chinese vaccine and there is the Johnson & Johnson vaccine to consider, and we are looking at a number of others,” she added.
Green light for Johnson & Johnson single shot
Later on Friday, WHO also announced it had given clearance to the vaccine developed by Janssen (Johnson & Johnson), for emergency use in all countries and for the international UN-partnered effort to roll-out vaccines equitably across the world, COVAX.
The decision comes on the back of the European Medicines Agency (EMA) authorization, which was announced on Thursday.
“Every new, safe and effective tool against COVID-19 is another step closer to controlling the pandemic,", said WHO Director-General, Dr Tedros Adhanom Ghebreyesus.
“But the hope offered by these tools will not materialize unless they are made available to all people in all countries. I urge governments and companies to live up to their commitments and to use all solutions at their disposal to ramp up production so that these tools become truly global public goods, available and affordable to all, and a shared solution to the global crisis.”
The vaccine from Janssen is the first to be listed by WHO as a single dose shot, which should facilitate vaccination logistics in all countries, the agency said. "The ample data from large clinical trials shared by the company also shows that the vaccine is effective in older populations", said the agency in a press release.
As of Friday 12 March, there have been 118,058,503 confirmed cases of COVID-19, including 2,621,046 deaths, reported to the UN health agency.
The highest number of cases of confirmed infection continues to be in the Americas, with 52,386,995, followed by Europe (40,438,291), South-East Asia (13,819,871), Eastern Mediterranean (6,793,641), Africa (2,924,244) and Western Pacific (1,694,716).
The development comes after several European countries suspended the rollout of the jab as a precaution.